DOCSLIB.ORG

Pharmacologic Treatment Possibilities Disclosures the Neurobiology Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacologic Treatment Possibilities Disclosures the Neurobiology Of 9/23/2015 Disclosures The Biopsychosocial Perspective: • No financial disclosures to share Pharmacologic Treatment Possibilities Roya L. Rezaee MD, FACOG Assistant Professor, Department of Reproductive Biology Co-Director, Program for Sexual Health and Vulvovaginal Disorders 2 The Neurobiology of Female Sexual Function NeuralA. PET Basis scan – healthy of female HSDD B. PET scan – HSDD female Female sexual function appears to be modulated by specific neurotransmitters, brain structures, and neurohormones • Dopamine • Basal ganglia • Estrogen • Serotonin • Amygdala • Testosterone Images supplied courtesy of Gert Holstege • Insular cortex •Oxytocin MD PhD • Epinephrine • Neuroimaging studies comparing premenopausal women • Norepinephrine • Caudate nucleus • Endogenous opioids with and without HSDD reveals differences in brain activity a,b,c,d • Hypothalamus • Pheromones patterns when shown erotic stimuli. • For women with HSDD their prefrontal cortex is unable to • Spinal cord deactivate, frustrating their ability to feel sexual desire. •Pituitary • The prefrontal cortex is responsible for executive functions • Hippocampus such as coordination of tasks, problem solving and information analysis. Taylor M, et al. J Affect Disord. • Ventral tegmental area 2005;88:241-254. aDifferences in Brain Activity in Premenopausal Women with Hypoactive Sexual Desire Disorder Compared to Women without Sexual Dysfunction Basson R. N Engl J Med. bBrain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual 2006;354:1497-1506. function: a cross‐sectional pilot study. Fertility and Sterility 2013. cWomen with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009. dNeural bases of hypoactive sexual desire disorder in women: an event‐related fmri study. Journal of Sexual Medicine 2011. 1 9/23/2015 Role of Steroid Hormones Role of Steroid Hormones • Estradiol • Testosterone and DHT are most potent and • maintains vaginal lubrication, blood flow to clitoris, urethra and vagina almost entirely bound by albumin and SHBG • Produced in granulosa cells of the ovary in – Remaing 1-2% of total is freely circulating and premenopausal women available to estrogen and testosterone sensitive • Estrone, estriol present have lower numbers and less tissues (including brain and skin) affinity for receptors • SHBG synthesized in the liver • Postmenopause • estrogen deficient state – Estrogen increases, testosterone decreases synthesis • Produced by precursors dehydroepiandosterone (DHEA), dehydroepiandosterone sulphate(DHEAS) • Affected by medication via first pass and androstenedion (A4) in the adrenal glands and ovary metabolism Role of Steroid Hormones Sex Hormone-Binding Globulin • Prohormones: DHEAS, DHEA, A4 converted . SHBG is the carrier protein for estrogen and into testosterone (T) and dihydrotestosterone testosterone (DHT) – SHBG-bound fraction is unavailable for • Ovary via the theca cells produces 25% of T, biological activity 50% of A, and 20% of DHEA . Production regulated by estrogen- • Adrenal Gland produces 25% of T, 50% of A, testosterone balance 50% of DHEA and 100% of DHEAS – Remaining 30% of DHEA is peripheral conversion of – Estrogen stimulates SHBG production by DHEAS the liver • Testosterone is also produced in the central – Testosterone decreases SHBG synthesis nervous system starting from cholesterol – Implications for treatment Selby C. Ann Clin Biochem. 1990;27:532-541. 2 9/23/2015 CNS Effects of Hormones on Female Role of Neurotransmitters/Signaling Molecules Sexual Function • Exact central neuroendocrine mechanism remains unclear • Involved areas of the brain: brain stem, hypothalamus, forebrain (amygdala) • Excitatory factors • Estrogen, testosterone, melanocortin, oxytocin, dopamine and norepinephrine • Inhibitory Factors • Serotonin, prolactin, endogenous opioids • The Balance is…”the sexual tipping point.” Perlman MA. The sexual tipping point. J Sex Med 2009 Adapted from: Clayton AH. Psychiatr Clin North Am. 2003;26:673‐682; Ben Zion IZ et al. Mol Psychiatry. 2006;11:782‐786 Physiology of Sexual Function Central Nervous System Role of Neuroendocrine Molecules - Testosterone 5-HT Progesterone • On the cellular level it is nitric oxide (NO), vasoactive +/‐ + + + peptide (VIP) and acetylcholine (ACh) that interact for Melanocortins sexual arousal + Estrogen + + • Based upon penile erection and animal studies Desire Dopamine (DA) - • Sexual stimulation releases NO from vascular + epithelium 5-HT - • Stimulates guanylate cyclase to guanosine Prolactin - Subjective + Norepinephrine (NE) Excitement triphosphate into guanosine monophospate (cGMP) • Stimulates smooth muscle relaxation in the penile arteries and corpora cavernosum causing increased + blood flow Oxytocin Orgasm Berman JR et al. World J Urol 2002 Clayton A, Hamilton D. Psychiatr Clin N Am. 2010;33:323-338. *slide adapted from website herdesire.net 3 9/23/2015 Physiology of Sexual Function Peripheral Tissues: effects of neurotransmitters and hormones Role of Neuroendocrine System • Drive is triggered in the hypothalamus and activates the dopamine system Gonads • System is activated early, norepinephrine is released, Adrenals sexual excitation increases and desire to continue 5-HT sexual activity continues - • Estrogen • Heart rate, blood pressure increase suggesting the Maintain Genital Structure Nitric Oxide (NO) • Testosterone and Function activation of the noradrenergic system • Progestin + - 5-HT2A + • Neurobiology of the orgasm is unknown although NE includes the mesolimbic dopamine pathway, pudendal, + pelvic and hypogastric nerves Vasocongestion Sensation Clitoral and • Orgasm occurs with the release of contracting agents - Penile Tissue oxytocin and serotonin in the tissue 5-HT + + Prostaglandin E • Leads to rhythmic contractions of levator plate, Cholinergic Fibers uterus, vagina Clayton A, Hamilton D. Psychiatr Clin N Am. 2010;33:323-338. • Resolution varies *adapted slide from website herdesire.net Desire in the brain… Excitatory CS-UCS Integrator Inhibitory Appetitive responses ACC CPu CB1s DA +++ VP NAcc 5-HT Pir Ctx MSH ++ ArcN How does this translate into DA +++ , 5-HT NE CB1s , pharmacologic treatment options? mPOA VTA GnRH OT++ NE PVN DA +++ NE , 5-HT Sexual reward Tu VMH LS CS detector UCS detector Olfactory cue MeApd Sexual reward OT Pfaus J G, Ismail N and Coria-Avila G A (2010) Sexual Motivation. In: Koob G.F., Le Moal M. and Thompson R.F. 16 (eds.) Encyclopedia of Behavioral Neuroscience, volume 3, pp. 201–209 Oxford: Academic Press 4 9/23/2015 Drugs In Development or Approved for Low Desire : Biological Approaches for Low Desire Drug Name Drug Pharma Current Developmental Status Category Sponsor Flibanserin Non-hormonal Sprout Approved 8/2015 for • Increase androgens (locally(DHEA) and CNS agent Pharmaceuticals HSDD in premenopausal women, available 10/17/15 Lybrido (on demand oral sildenafil + Emotional Brain Phase II completed for HSDD systemically) tablet) testosterone Lybridos (on demand oral buspirone + Emotional Brain Phase II in progress for HSDD • Increase dopamine tablet) testosterone DHEA Vaginal Ovules Androgenic EndoCeutics, Inc. Phase III completed for VVA in postmenopausal • Increase norepinephrine (Prasterone) Precursor for VVA Bayer Women;future investigation for HSDD Bremelanotide (PT-141) melanocortin Palatin Phase IIB for FSAD completed • Modulate serotonin subq injection (PL6983) receptor modulator Technologies Phase III underway for HSDD/FSIAD Extended release daily oral bupropion and SP-1 Biopharma Phase III set to begin buspirone and bupropion trazodone • Melanocortins (LorexysTM) • PDE-5 Inhibitor 17 Sexual Desire: Estrogen Testosterone Biological Approaches Excitatory and Inhibitory Pathways Bupropion SR Lorexys Flibanserin Lybrido/Lybridos + Bremelanotide • Increase androgens (locally(DHEA) and Inhibitory Excitatory systemically) • Increase dopamine 5-HT Testoterone, Prolactin Estrogen, Opioids • Increase norepinephrine Dopamine Endocannabinoids Norepinephrine Oxytocin Melanocortins • Modulate serotonin • Melanocortins • PDE-5 Inhibitor Adapted from Pfaus J. J Sex Med. 2009;6:1506-1533. 20 5 9/23/2015 Published Randomized Studies Demonstrating Efficacy of Testosterone for Low Desire Testosterone in Postmenopausal Women Doses (mcg/d) Subjects (n) Estrogen - Testosterone Shifren et al, 2000 150/300 SM (75) + 5-HT Progesterone Braunstein, +/‐ + 150/300/450 SM (447) + + + et al 2005 Melanocortins Buster et al, 2005 300 SM (533) + Estrogen + + + Desire Dopamine (DA) Simon et al, 2005 300 SM (562) + - + Davis et al 2006 300 SM (61) + (patch) 5-HT - + (aromatase Prolactin - Subjective + Davis et al, 2006 300 SM (76) Norepinephrine (NE) inhibitors) Excitement Shifren et al, 2006 300 NM (486) + Liu et al, 2008 300 NM (431) + + Oxytocin Orgasm Davis et al, 2008 150/300 NM/SM (814) - Panay et al, 2010 300 NM (272) +/- groups NM= naturally menopausal SM= surgically menopausal Adapted from Clayton A, Hamilton D. Psychiatr Clin N Am. 2010;33:323-338 slide adapted from herdesire.net. Off-Label Testosterone Options Davis & Braunstein: Summary of Efficacy & Safety for Low Desire • Randomized, double-blind placebo controlled studies have • Testosterone transdermal patches established efficacy of transdermal patch for relieving symptoms of HSDD in naturally and surgically menopausal women with and • Testosterone gels and patches approved for men without concomitant estrogen or estrogen/ progesterone therapy • Compounded
Load more

Recommended publications
  • Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?
    Physiol. Res. 52: 397-407, 2003 MINIREVIEW Dehydroepiandrosterone – Is the Fountain of Youth Drying Out? P. CELEC 1,2, L. STÁRKA3 1Faculty of Medicine, 2Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia and 3Institute of Endocrinology, Prague, Czech Republic Received September 15, 2002 Accepted October 7, 2002 Summary Dehydroepiandrosterone (DHEA) and its sulphate-bound form (DHEAS) are important steroids mainly of adrenal origin. Their physiological and pathophysiological functions are not yet fully identified, although a number of various possible features have been hypothesized. Most popular is the description of the “hormone of youth” as the long-term dynamics of DHEA levels are characterized by a sharp age-related decline in the late adulthood and later. Low levels of DHEA are, however, associated not only with the ageing process but also with diabetes mellitus, cardiovascular diseases and some neurological or immunological entities. In the past decade, a number of brief studies have concentrated on these relationships and also on the role of exogenous DHEA in health, disease and human well-being. This article tries to summarize some of the most important facts achieved recently. Key words Dehydroepiandrosterone • Intracrinology • Hormone replacement therapy • Steroids Introduction functions: 1) DHEA is an endogenous metabolite that cannot be patented so that pharmaceutical companies are In 1934 Butenandt and Dannenbaum isolated not interested in supporting research in this field. dehydroepiandrosterone (DHEA) from urine and in 1944 2) DHEA can be described as a “human molecule” Munson and colleagues identified its 3β-sulphate because other investigated species have much lower (DHEAS). Even now, nearly 70 years later, we still do concentrations.
    [Show full text]
  • Comparison of the Effects of High Dose Testosterone and 19-Nortestosterone to a Replacement Dose of Testosterone on Strength and Body Composition in Normal Men
    J. Steroid Biochem. Molec. Biol. Vol. 40, No. 4-6, pp. 607~12, 1991 0960-0760/91 $3.00 + 0.00 Printed in Great Britain Pergamon Press plc COMPARISON OF THE EFFECTS OF HIGH DOSE TESTOSTERONE AND 19-NORTESTOSTERONE TO A REPLACEMENT DOSE OF TESTOSTERONE ON STRENGTH AND BODY COMPOSITION IN NORMAL MEN KARL E. FRIEDL,* JOSEPH R. DETTORI, CHARLES J. HANNAN JR, TROY H. PATIENCE and STEPHENR. PLYMATE Exercise Physiology Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA and Department of Clinical Investigation, Madigan Army Medical Center, Tacoma, WA, U.S.A. Summary--We examined the extent to which supraphysiological doses of androgen can modify body composition and strength in normally virilized men. In doubly blind tests, 30 healthy young men received testosterone enanthate (TE) or 19-nortestosterone decanoate (ND), at 100mg/wk or 300mg/wk for 6 weeks. The TE-100mg/wk group served as replacement dose comparison, maintaining pretreatment serum testosterone levels, while keeping all subjects blinded to treatment, particularly through reduction in testicular volumes. Isokinetic strength measurements were made for the biceps brachii and quadriceps femoris muscle groups before treatment and 2-3 days after the 6th injection. Small improvements were noted in all groups but the changes were highly variable; a trend to greater and more consistent strength gain occurred in the TE-300mg/wk group. There was no change in weight for TE-100 mg/wk but an average gain of 3 kg in each of the other groups. No changes in 4 skinfold thicknesses or in estimated percent body fat were observed.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis
    ORIGINAL ARTICLE Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis Ana E. Espinosa De Ycaza, Robert A. Rizza, K. Sreekumaran Nair, and Michael D. Jensen Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905 Downloaded from https://academic.oup.com/jcem/article/101/4/1719/2804555 by guest on 24 September 2021 Context: Dehydroepiandrosterone (DHEA) and T hormones are advertised as antiaging, antiobe- sity products. However, the evidence that these hormones have beneficial effects on adipose tissue metabolism is limited. Objective: The objective of the study was to determine the effect of DHEA and T supplementation on systemic lipolysis during a mixed-meal tolerance test (MMTT) and an iv glucose tolerance test (IVGTT). Design: This was a 2-year randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at a general clinical research center. Participants: Sixty elderly women with low DHEA concentrations and 92 elderly men with low DHEA and bioavailable T concentrations participated in the study. Interventions: Elderly women received 50 mg DHEA (n ϭ 30) or placebo (n ϭ 30). Elderly men received 75 mg DHEA (n ϭ 30),5mgT(nϭ 30), or placebo (n ϭ 32). Main Outcome Measures: In vivo measures of systemic lipolysis (palmitate rate of appearance) during a MMTT or IVGTT. Results: At baseline there was no difference in insulin suppression of lipolysis measured during MMTT and IVGTT between the treatment groups and placebo. For both sexes, a univariate analysis showed no difference in changes in systemic lipolysis during the MMTT or IVGTT in the DHEA group and T group when compared with placebo.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • Uses of Bremelanotide in Therapy for Female Sexual
    (19) TZZ __T (11) EP 2 916 856 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 38/12 (2006.01) 19.09.2018 Bulletin 2018/38 A61P 15/00 (2006.01) C07K 7/64 (2006.01) (21) Application number: 13851014.4 (86) International application number: PCT/US2013/068386 (22) Date of filing: 05.11.2013 (87) International publication number: WO 2014/071339 (08.05.2014 Gazette 2014/19) (54) USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION VERWENDUNG VON BREMELANOTID IN DER THERAPIE VON WEIBLICHER SEXUELLER DYSFUNKTION UTILISATIONS DE BRÉMÉLANOTIDE DANS UNE THÉRAPIE DE DYSFONCTIONNEMENT SEXUEL FÉMININ (84) Designated Contracting States: • "Palatin Technologies Presents Positive Results AL AT BE BG CH CY CZ DE DK EE ES FI FR GB for Phase 2B Bremelanotide Female Sexual GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Dysfunction Trial", PRNewswire , 8 November PL PT RO RS SE SI SK SM TR 2012 (2012-11-08), XP002757483, Retrieved from the Internet: (30) Priority: 05.11.2012 US 201261722511 P URL:http://www.palatin.com/investors/press 28.02.2013 US 201361770535 P -releases/ [retrieved on 2016-05-09] • ROSEN R C ET AL: "Evaluation of the safety, (43) Date of publication of application: pharmacokineticsand pharmacodynamic effects 16.09.2015 Bulletin 2015/38 of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male (73) Proprietor: Palatin Technologies, Inc. subjects and in patients with an inadequate Cranbury NJ 08512 (US) response to Viagra(R)", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, (72) Inventors: STOCKTON, BASINGSTOKE, GB, vol.
    [Show full text]
  • Testosterone, Injectable
    Clinical Criteria Subject: Testosterone, Injectable Document #: ING-CC-0026 Publish Date: 06/10/201909/23/2019 Status: ReviewedRevised Last Review Date: 03/18/201908/16/2019 Table of Contents Overview Coding References Clinical criteria Document history Overview This document addresses indications for the intramuscular (IM) and subcutaneous (SC) administration of testosterone injectables for the treatment of hormone deficient conditions. The following testosterone injection agents are included: • Testosterone cypionate intramuscular: Depo-Testosterone, generic testosterone cypionate • Testosterone enanthate: o Intramuscular: generic testosterone enanthate o Subcutaneous: Xyosted (auto-injector) • Testosterone undecanoate intramuscular: Aveed Testosterone is an androgen hormone responsible for normal growth and development of male sex characteristics. In certain medical conditions such as hypogonadism, the endogenous level of testosterone falls below normal levels. Primary hypogonadism includes conditions such as testicular failure due to cryptorchidism, bilateral torsion, orchitis, or vanishing testis syndrome; bilateral orchidectomy; and inborn errors in the biosynthesis of testosterone. Secondary hypogonadism, also called hypogonadotropic hypogonadism includes conditions such as gonadotropin-releasing hormone (GnRH) deficiency or pituitary-hypothalamic injury resulting from tumors, trauma, surgery, or radiation. In 2015, the Endocrine Society added the following amended recommendations: • Men with metabolic syndrome, who were previously unexamined by the 2010 Endocrine Society Clinical Practice Guidelines, may benefit from testosterone replacement therapy (TRT) based on improvements in biometrics and insulin sensitivity. Effects of TRT on similar endpoints in men with type 2 diabetes mellitus remain unclear; • Effects of TRT on erectile function, even in men refractory to phosphodiesterase type 5 inhibitors, and on quality of life in men with erectile dysfunction remain inconclusive (Seftel, 2015).
    [Show full text]
  • Testosterone for Women...And Men
    Testosterone for Women...and Men Date: 05/08/2006 Posted By: Jon Barron Every now and then I get a break in putting together a newsletter. I get to steal the entire newsletter from myself. In this case, I was able to take most of the material for this newsletter from the formulation information I put together for my new upgraded Women's Formula that Baseline Nutritionals released this month. And while this newsletter definitely serves as an introduction to that new formula, it more importantly provides an excuse for exploring a crucial topic for both men and women -- the value of maintaining an optimum testosterone balance. However, before we get into the specifics of both the men's and women's formulas, let's explore what testosterone does in the body -- and why it's so important for both men and women. The 30,000 Mile Tune-Up: Hormonal Changes As men and women enter their 30's, profound changes begin to take place in their bodies. If not addressed (that's the 30,000 mile tune-up thing), these changes can lead to, among other things: • Decreased energy and zest for life • Loss of muscle tone and increased fat • Circulatory problems and decreased libido But it doesn't have to be this way. Let me explain. Hormonal Imbalance Hormones are the body's chemical messenger system. They tell the various cells of the body what to do - - and when to do it -- by attaching to specific receptor sites on individual cells. Problems occur when the various hormones get out of balance.
    [Show full text]
  • Failure of Vitamin B6 to Reverse the L-Dopa Effect in Patients on a Dopa Decarboxylase Inhibitor
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.34.6.682 on 1 December 1971. Downloaded from J. Neurol. Neurosurg. Psychiat., 34, 682-686 Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor HAROLD L. KLAWANS, STEVEN P. RINGEL. AND DAVID M. SHENKER From the Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA SUMMARY Seven patients with Parkinsonism previously on L-dopa were placed on a regimen of L-dopa and alpha methyl dopa hydrazine (a dopa decarboxylase inhibitor). Two of these patients had previously shown marked clinical deterioration of the L-dopa improvement when given pyrid- oxine. None of the seven patients receiving alpha methyl dopa hydrazine demonstrated any change in their condition when given pyridoxine. The failure of vitamin B6 to reverse the clinical effect of L-dopa in patients receiving both L-dopa and a peripheral dopa decarboxylase inhibitor suggests that reversal of the L-dopa effect induced by vitamin B6 is due to increasing the activity of the enzyme dopa decarboxylase outside the central nervous system. guest. Protected by copyright. In patients with Parkinsonism receiving L-dopa hydrazine). These observations help to explain the (L-3, 4-dihydroxyphenylalanine), vitamin B6 has paradoxical effects of large amounts of pyridoxine recently been shown to cause a loss or reversal of in patients receiving L-dopa. the L-dopa effect (Duvoisin, Yahr, and Cote, 1969; Yahr, Duvoisin, Schear, Barrett, and Hoehn, METHODS AND RESULTS 1970). This was discovered when Duvoisin et al. (1969) gave vitamin B6 to patients receiving L-dopa Seven patients with Parkinsonism who had been on in an attempt to increase formation of dopamine L-dopa for at least one year were included in this from L-dopa within the central nervous system (CNS) study.
    [Show full text]
  • Preclinical Effects of Melanocortins in Male Sexual Dysfunction
    International Journal of Impotence Research (2008) 20, S11–S16 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir Preclinical effects of melanocortins in male sexual dysfunction AM Shadiack1 and S Althof2 1Locus Pharmaceuticals, Blue Bell, PA, USA and 2The Center for Marital and Sexual Health of South Florida, West Palm Beach, FL, USA The neurobiology of sexual behavior involves the interrelationships between sex steroids and neurotransmitters that result in both central nervous system (CNS) effects and effects in the genitalia. Tools such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) scanning can help determine what areas of the brain are activated under sexual stimulation. Our understanding of the role of various neurotransmitters, neurosteroids and other CNS-acting compounds is improving. The role of CNS-acting compounds such as dopamine agonists in the treatment of male sexual dysfunction is under active investigation. Melanocortins have CNS and peripheral roles in a wide variety of bodily functions. The melanocortin agonist bremelanotide appears to act in the CNS to promote erections in preclinical models, and may also stimulate behaviors that facilitate sexual activity beyond their erectogenic effects. International Journal of Impotence Research (2008) 20, S11–S16; doi:10.1038/ijir.2008.17 Keywords: erectile dysfunction; neuroanatomy; neurophysiology; CNS-acting agents; melanocortins; bremelanotide Introduction Neuroanatomy of male sexual response The neurobiology of sexual behavior involves the Sex and the brain interrelationships between sex steroids and neuro- Sexual arousal can now be studied with such transmitters that result in both central nervous sophisticated tools as PET (positron emission system (CNS) effects and effects in the genitalia.
    [Show full text]